For instance, In July 2024, the MHRA approved Semaglutide, a GLP-1 receptor agonist, to reduce the risk of major cardiovascular events in obese or overweight people, underscoring its expanding benefits beyond glycemic control In December 2023, Eli Lilly and Company launched Zepbound (tirzepatide), the first dual GIP/GLP-1 receptor agonist for chronic weight management in adults with obesity or other weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease Together, such developments are reshaping the role of GLP-1 analogues from single-purpose treatments to comprehensive metabolic health solutions
This relatively shorter half-life means that PPG control occurs mainly in the meal after injection [18]
Over the past two years, Jasper Colin has conducted extensive interviews with diabetes patients and GLP-1 users, building real-world understanding of how appetite suppression translates into lifestyle rewiring across food, beverages, retail, fitness, beauty, and healthcare behaviors
rather, it reflects how strongly GLP-1 receptors affect gastric emptying and gut motility before the body has time to adapt
Note to Publisher: Pricing information verified via screenshots from official checkout pages dated January 2026
